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A B S T R A C T
Introduction. Angiotensin-converting enzyme 2 (ACE2) is a key enzyme of the renin angiotensin system, which
breaks down angiotensin II and forms angiotensin-(1–7). In erectile tissues, it has been documented that angiotensin
II contributes to the development of erectile dysfunction (ED), while treatment with angiotensin-(1–7) improves
penile erection. However, the expression and function of ACE2 in erectile tissues have never been investigated.
Aim. Here, we examined the expression of ACE2 in erectile tissues and its actions against hypercholesterolemia-
induced corpus cavernosum (CC) injury.
Methods. Hypercholesterolemic apolipoprotein E knockout (ApoE−/−) mice, a well-known model of ED, were
treated with diminazene aceturate (DIZE), an ACE2 activator compound, or vehicle for 3 weeks. Reactive oxygen
species (ROS), collagen content, and protein expression of ACE2, neuronal nitric oxide synthase (nNOS), endo-
thelial nitric oxide synthase (eNOS), nicotinamide adenine dinucleotide phosphate-oxidase (NADPH) subunits were
evaluated in the penis of DIZE-treated and untreated ApoE−/− mice. Functional studies were performed in CC strips.
Main Outcome Measures. ACE2 expression and its role in modulating nitric oxide (NO)/ROS production and
ﬁbrosis within the CC of hypercholesterolemic mice were the main outcome measures.
Results. ACE2 was expressed in smooth muscle and endothelial cells of mouse CC. Interestingly, ACE2 was
downregulated in penis of hypercholesterolemic mice with ED, suggesting a protective role of ACE2 on the CC
homeostasis. In accordance with that, pharmacological ACE2 activation by DIZE treatment reduced ROS produc-
tion and NADPH oxidase expression, and elevated nNOS and eNOS expression and NO bioavailability in the penis
of ApoE−/− mice. Additionally, DIZE decreased collagen content within the CC. These beneﬁcial actions of DIZE
on the CC were not accompanied by improvements in atherosclerotic plaque size or serum lipid proﬁle.
Conclusion. ACE2 is expressed in erectile tissue and its reduction is associated with hypercholesterolemia-induced
ED. Additionally, treatment with DIZE improved hypercholesterolemia-induced CC injury, suggesting ACE2 as a
potential target for treating ED. Fraga-Silva RA, Costa-Fraga FP, Montecucco F, Sturny M, Faye Y, Mach F,
Pelli G, Shenoy V, da Silva RF, Raizada MK, Santos RAS, and Stergiopulos N. Diminazene protects corpus
cavernosum against hypercholesterolemia-induced injury. J Sex Med 2015;12:289–302.
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Introduction
The renin angiotensin system (RAS) is a keymodulator of cardiovascular homeostasis [1–3].
Also, evidences indicate that RAS also plays an essen-
tial role in erectile function [4–10]. Besides endo-
crinal actions, the RAS is articulated within the
cavernosal tissue and acts in a paracrine manner,
modulating corpus cavernosum (CC) smooth muscle
cell activity [4,8,10]. In fact, the physiological
amount of angiotensin II (Ang II), the main RAS
effector, produced in erectile tissues is signiﬁcantly
higher than those found in the systemic circulation
[4], indicating an intense modulation of RAS in the
erectile tissues. Within the CC, Ang II produces
smooth muscle cell contraction and oxidative stress
and decreases nitric oxide (NO) bioavailability
[8,11,12]. Moreover, it was reported that Ang II
levels in penile plasma were elevated in patients with
erectile dysfunction (ED) [4], suggesting that the
hyperactivity of this peptide is closely associated with
the pathogenesis of ED.
Conversely, Ang-(1–7), known as a pivotal contra-
regulator of Ang II, appears to mediate penile erec-
tion [6,7,9]. Ang-(1–7) produces CC relaxation and
NO release and potentiates erection by acting
through Mas receptor [7]. This peptide is mainly
formed by angiotensin-converting enzyme 2
(ACE2), which cleaves the C-terminal phenylalanine
of Ang II, leading to Ang-(1–7) formation [13–15].
Thus, ACE2 is a key enzyme of the RAS that reduces
Ang II and increases Ang-(1–7) bioavailability.
However, the expression and function of this enzyme
have never been investigated in erectile tissues.
Recently, a novel pharmacological strategy has
been developed to target ACE2. Based on the crystal
3D structure of ACE2 and using a virtual screening
strategy, about 140,000 small molecules (from a
chemical library) were molecularly docked into
structural pockets present in structures of ACE2 in
different conformations [16]. Small molecules able to
interact with a speciﬁc pocket of this enzyme were
able to maintain a favorable conformation for
optimal activity, consequently activating the enzyme
[16]. It was documented that two compounds are
able to activate ACE2, a xanthenone called XNT
[16–19] and diminazene aceturate (DIZE) [20–22]. It
has been shown that ACE2 activator compounds
produce several beneﬁcial cardiovascular effects [16–
22]. For instance, DIZE attenuates pulmonary
hypertension [20], reduces damages in cardiac [21]
and stroke ischemia [22], and has other beneﬁcial
outcomes [23,24]; however, its action on erectile
tissues has never been addressed.
In the present study, we aim to evaluate the
expression of ACE2 in erectile tissue. Moreover,
we sought to investigate if treatment with the
novel ACE2 activator compound, DIZE, would




A well-established animal model of hypercholes-
terolemia-induced ED was used [25–27]. This ED
model was chosen foremost because hypercholester-
olemia is one of the most prevalent risk factors for
the development of ED [28,29]. Moreover, the
pathophysiological mechanism of hypercholesterol-
emic ED condition involves molecular pathways
related to actions of the RAS on systemic vasculature
and CC, such as modulation of oxidative stress, NO
bioavailability, and matrix collagen deposition
[28,30–33]. Apolipoprotein E knockout (ApoE−/−)
mice in a C57BL/6J background (N = 40) were
obtained from Charles River Laboratories (Les
Oncins, France). Animals at 15–20 weeks of age were
randomly assigned in two groups: (i) treated with the
ACE2 activator DIZE [20] and (ii) treated with
vehicle (saline 0.9%). During the 11-week experi-
mental period, the animals were fed with Western-
type diet consisting of 15% (wt/wt) cocoa butter and
0.25% (wt/wt) cholesterol (Diet W, cat# 4021.06,
abDiets, Woerden, Netherlands). The mice were
administered with DIZE (15 mg/kg per day, pro-
vided by Prof. Raizada) or vehicle subcutaneously
during the last 3 weeks. After experimental period,
the animals were anesthetized (ketamine 100 mg/kg,
xylazine 10 mg/kg) and blood samples were collected
by cardiac puncture for serum extraction. Immedi-
ately following cardiac puncture, the penis was
removed and snap-frozen in liquid nitrogen and
stored at −80°C for protein measurements or frozen
in cryoembedding medium for histological analysis.
Some penises were excised and mounted in the iso-
lated organ bath as described below. Age-matched
C57BL/6J wild type mice (n = 20) fed with standard
diet were used as additional controls. All animal
study was approved by local ethics committee and
Swiss authorities and is in accordance with the
United States National Institutes of Health (NIH)
guidelines.
Dosage of Serum Lipid Profile
Serum lipid proﬁle was routinely measured on
total blood and expressed as millimole per liter.
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Brieﬂy, blood samples were collected by cardiac
puncture, incubated at room temperature for 15
minutes (for clotting), and the serum was sequen-
tially obtained by centrifugation (4,500 rpm for 10
minutes). The lipids were measured by photomet-
ric enzymatic reaction using commercial available
kits (total cholesterol, cat. number: #12016630;
low-density lipoprotein cholesterol [LDL-c], cat.
number: #03038661; high-density lipoprotein
cholesterol [HLDL-c] from Roche Diagnostics
GmbH, Mannheim, Germany) using the chemis-
try analyzer Roche Hitachi 902 (Roche Diagnos-
tics GmbH). The assay was performed as
described in the instruction manual.
Immunostaining in Mouse Penis
The expression and localization of ACE2 in mouse
penis were assessed by co-immunostaining of ACE2
with CD31 and α-actin. Six-micrometer cryosec-
tions of wild type and ApoE−/− mice penises were
ﬁxed in acetone at room temperature and immuno-
stained overnight with the following primary anti-
bodies: anti-ACE2 (1:100, cat# sc-20998, Santa Cruz
Biotechnology, Inc., Dallas, TX, USA); anti-α-actin
(1:100, cat# sc-32251, Santa Cruz Biotechnology,
Inc.); and anti-CD31 (1:100, cat# sc-1506, Santa
Cruz Biotechnology, Inc.). Sequentially, the follow-
ing second antibodies were used: anti-rabbit immu-
noglobulinG (IgG) conjugatedwith Alexa Fluor-555
secondary antibody (1:400, cat# A31572, Invitrogen,
Inc., Carlsbad, CA, USA); anti-mouse IgG conju-
gated with Alexa Fluor-647 secondary antibody
(1:400, cat# A31571, Invitrogen, Inc.); and anti-goat
IgG conjugated with Alexa Fluor-488 secondary
antibody (1:400, cat# A21467, Invitrogen, Inc.). The
sections were ﬁnally closed with coverslip and
mounting medium containing DAPI (Vectashield®,
cat# H-1200, Vector Laboratories, Inc., Burlingame,
CA, USA) and examined on a confocal microscope
equipped with a digital imaging system (Carl Zeiss
LSM 700, Carl Zeiss LSM, Zeiss, Oberkochen,
Baden-Württemberg, Germany).
Western Blotting of ApoE−/− Mouse Penis
The protein expressions of ACE2, neuronal
(nNOS) and endothelial (eNOS) nitric oxide
synthases, and nicotinamide adenine dinucleotide
phosphate-oxidase (NADPH) subunits p67-phox
(p67) and p22-phox (p22) were evaluated by
western blotting. Forty micrograms of protein
extracted from mice penises was run on a 10%
sodium dodecyl sulfate-polyacrylamide electro-
phoresis gel and the proteins were transferred onto
a polyvinylidene ﬂuoride membrane. After block-
ing for 1 hour (Li-Cor Odyssey Blocking Buffer,
cat# 927-40000, Li-Cor Biosciences, Lincoln, NE,
USA), the membranes were probed with one of the
following primary antibodies: anti-ACE2 (1:100,
cat# sc-20998, Santa Cruz Biotechnology, Inc.);
anti-eNOS (dilution 1:200, cat# sc-654, Santa
Cruz Biotechnology, Inc.); anti-nNOS (dilution
1:200, cat# sc-8309, Santa Cruz Biotechnology,
Inc.); anti-p22 (dilution 1:200, cat# sc-11712,
Santa Cruz Biotechnology, Inc.); anti-p67 (dilu-
tion 1:200, cat# sc-7663, Santa Cruz Biotechnol-
ogy, Inc.); and anti-α-actin (dilution 1:600, cat#
32251, Santa Cruz Biotechnology, Inc.). Mem-
branes were washed three times for 10 minutes in
tris-buffered saline-Tween and incubated with
anti-mouse IgG conjugated with IRDye 680 sec-
ondary antibody (dilution 1:3,000, cat# 926-
68072, Li-Cor Biosciences) or anti-goat IgG
conjugated with IRDye 800 secondary antibody
(dilution 1:3,000, cat# 926-32214, LiCor, Inc.) or
anti-rabbit IgG conjugated with IRDye 800 sec-
ondary antibody (dilution 1:3,000, cat# 926-
32213, LiCor, Inc.) for 2–3 hours at room
temperature. After a series of ﬁnal washes
(phosphate-buffered solution [PBS]), the blots
were detected using a ﬂuorescence detector
(Odyssey Imaging System, Li-Cor Biosciences).
Detection of Reactive Oxygen Species in CC
Reactive oxygen species (ROS) detection in mice
CC was performed by dihydroethidium (DHE;
Sigma-Aldrich, St. Louis, MO, USA, cat# 37291)
staining. Cryosections of 6 μm were allowed to
thaw at room temperature and sequentially washed
with PBS. Later, the sections were stained with
DHE at 2 μmol/L in PBS for 20 minutes at 37°C
in dark. The slices were washed with PBS, closed
with coverslip and mounting medium containing
DAPI, and examined on a confocal microscope
(Carl Zeiss LSM 700). DHE ﬂuorescence inten-
sity of acquired digital images was quantiﬁed by
Image J software (NIH, Bethesda, MD, USA).
Total Nitrite and Nitrate Assay in Serum
Nitrite (NO2−) and nitrate (NO3−) were measured
as an indirect measurement of NO content in
mouse serum using a commercially available kit
(Griess assay; R&D Systems, Minneapolis, MN,
USA, cat# KGE001). Prior to conducting the
assay, serum was ﬁltered using a 10,000 molecular
weight cutoff ﬁlters (cat# UFC501096, Millipore,
Billerica, MA, USA). The assay was performed as
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described previously [31] and according to the
manual instructions. Each sample was run as a
technical triplicate.
Functional Studies in Cavernosal Tissue
After euthanasia, penises were excised and dis-
sected in Krebs–Henseleit buffer (mmol/L: NaCl
110.8, KCl 5.9, NaHCO3 25.0, MgSO4 1.07,
CaCl2 2.49, NaH2PO4 2.33, and glucose 11.51).
The tunica albuginea was carefully removed and
the strip preparations were obtained. Cavernosal
strips were mounted in isolated organ chamber
system containing Krebs–Henseleit buffer at 37°C
and continuously aerated with a mixture of 95%
O2 and 5% CO2. The mechanical activity was
recorded isometrically by a force transducer
(ADInstruments, Colorado Springs, CO, USA).
The tissue was stretched to a passive force of
3.0 mN and allowed to equilibrate for 60 minutes,
and the solutions were replaced every 15 minutes
[31]. Changes in isomeric force were recorded
using a PowerLab/8SP data acquisition system
(Chart software, version 5.0; ADInstruments).
To evaluate cavernosal endothelial function, the
endothelial-dependent relaxation was induced by
acetylcholine (ACh, 10−9 mol/L to 10−6 mol/L)
in strips pre-constricted with phenylephrine
(10−5 mol/L). To correct the differences in vascular
smooth muscle reactivity, the response to ACh was
normalized by the sodium nitroprusside (SNP)
response (10−4 mol/L).
Sirius Red Staining for Collagen Content in
Mouse Penis
Sirius red staining was performed in penis
cryosections as described previously [27,31].
Brieﬂy, mouse penis cryosections (6 μm) were
rinsed with water; nuclei were stained with
Weigert’s hematoxylin for 10 minutes, washed in
tap water, and incubated with 0.1% Sirius red
(Sigma Chemical Co, St Louis, MO, USA) in satu-
rated picric acid for 60 minutes. Sections were
rinsed twice with 5% acetic acid in water for 10
seconds, then immersed in absolute ethanol three
times before clearing in xylene twice and cover-
slipping. The sections were photographed with
identical exposure settings under ordinary light
microscopy. Quantiﬁcations were performed
with Image J software.
Atherosclerotic Lesion Analysis
For quantiﬁcation of atherosclerotic lesions, en
face with Oil-red-O was performed in aortic tree
of ApoE−/− mice. After sacriﬁce, arterial trees were
perfused with PBS and dissected from the heart,
extending 2–3mm after the bifurcation of the iliac
arteries. After ﬁxation in 4% paraformaldehyde for
24 hours, the aortas were opened longitudinally to
expose the area of deﬁnable lesion covering the
luminal en face surface. Oil-red-O staining was
carried out as previously described [34]. Images
were captured and the quantiﬁcation of stained
area was determined with Image J software.
Data Analysis
All results are expressed as mean ± standard error
of the mean. Statistical analyses for western blot,
Sirius red, and DHE staining were performed
using one-way analysis of variance (anova) fol-
lowed by Bonferroni posttest. Statistical analyses
for Griess assay, serum lipid, and Oil-Red-O stain-
ing red were done using Student t-test. Finally, the
statistical analyses of the corpus cavernosal tissue
bath experiments were performed using two-way
anova followed by Bonferroni posttest. A value of
P < 0.05 was considered signiﬁcant.
Results
ACE2 Is Expressed in Mouse Penis and It Is Reduced
in Hypercholesterolemic Mice
ACE2 protein expression was shown in CC of wild
type and ApoE−/− mice by immunostaining
(Figure 1). This enzyme expression was co-localized
with α-actin and CD31, markers for smooth muscle
and endothelial cells, respectively (Figure 1A). The
expression of ACE2 in the mouse penis was con-
ﬁrmed bywestern blotting (Figure 1B). Interestingly,
ACE2 protein expression was reduced in ApoE−/−
mice when compared with wild type (Figure 1C).
Additionally, 3 weeks of treatment with DIZE
increased its protein expression (Figure 1B, C) at
similar levels than wild type. These data revealed that
ACE2 is present in erectile tissues and its regulation
may differ under pathological conditions.
ACE2 Activation Decreases ROS Production in
ApoE−/− Mouse Penis
Based on the data showing the expression of ACE2
on the CC, we sought to evaluate if pharmacological
increase of this enzyme would produce beneﬁcial
effects against injures induced by hypercholesterol-
emia. As previously observed [28,35], we found that
ROS production was augmented in ApoE−/− mouse
penis (Figure 2), whichwas associated to an increased
protein expression of NADPH oxidase (Figure 3).
Remarkably, the treatment with DIZE decreases
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Figure 1 ACE2 is expressed in mouse penis. Immunostaining and western blotting analysis were used to detect
angiotensin-converting enzyme 2 (ACE2) on penis from wild type and apolipoprotein E knockout (ApoE−/−) mouse penis. (A)
ACE2 was strongly co-localized with α-actin (smooth muscle cells marker) as well as CD31 (endothelial cell marker) in the
corpus cavernosum and dorsal artery of wild type and ApoE−/− mice. The graphs show representative images obtained from
eight different animals. (B) ACE2 expression in the mouse penis was confirmed by western blotting, which revealed a specific
single band at the expected molecular weight. Additionally, ACE2 expression was reduced in ApoE−/− mouse penis when
compared with wild type, while 3 weeks of treatment with diminazene aceturate (DIZE) normalized this alteration. The graph
show representative gel of western blotting from three independent experiments. (C) Quantification of ACE2 protein
expression by western blotting. Data were normalized using α-actin. **P < 0.01 (One-way ANOVA followed by Bonferroni
post-test). A.U. = arbitrary unity; WT = wild type.
Figure 2 Angiotensin-converting enzyme 2 (ACE2) activation reduces reactive oxygen species (ROS) production induced by
hypercholesterolemia. Diminazene aceturate (DIZE) treatment decreases ROS content into corpus cavernosum of ApoE−/−
mice. (A) Quantification of ROS content. (B–G) Representative photomicrographs of penis sections showing the ROS
production using dihydroethidium (DHE) staining. Figure parts B–D show the corpus cavernosum and E–F show the dorsal
vessels area. **P < 0.01 and ***P < 0.001 (one-way analysis of variance [ANOVA] followed by Bonferroni posttest). Each column
represents the mean ± standard error of the mean (SEM) (n = 12) of relative fluorescence in arbitrary unity (A.U.).
ApoE−/− = apolipoprotein E knockout.
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ROS production in the CC of ApoE−/− mice to a
comparable level of wild type mice (Figure 2A–D).
Similarly, DIZE treatment also decreased ROS pro-
duction in the dorsal vessels of ApoE−/− mice
(Figure 2E–G). Accordingly, DIZE treatment
reduced the protein expression of NADPH oxidase
subunits p67 (Figure 3A, B) and p22 (Figure 3C, D)
in ApoE−/− mouse penis as compared with vehicle-
treated mice.
DIZE Increases NO Bioavailability in ApoE−/−
Mouse Penis
NO stable metabolites (NO2− and NO3−) in serum
samples were increased in DIZE-treated ApoE−/−
mice compared with untreated ApoE−/− mice
(Figure 5C). Because this result only indicates a sys-
temic vascular increase in NO production, we
decided to evaluate the local protein levels of
nNOS and eNOS. The eNOS and nNOS protein
Figure 3 Treatment with diminazene aceturate (DIZE) reduces nicotinamide adenine dinucleotide phosphate-oxidase
(NADPH) oxidase expression in penis from apolipoprotein E knockout (ApoE−/−) mice. (A and C) Quantification of NADPH
oxidase protein expression, subunits p67-phox (A) and p22-phox (C), was performed using western blotting in protein
extracted from penis of wild type, untreated, and DIZE-treated ApoE−/− mice. (B and D) Representative western blotting gels
of p67-phox (C) and p22-phox (D). Data were normalized using α-actin. *P < 0.05 (one-way analysis of variance [ANOVA]
followed by Bonferroni posttest). Each column represents the mean ± standard error of the mean (SEM) (n = 6 to 7) of
relative protein expression in arbitrary unit (A.U.) from three independent experiments. n.s. = nonsignificant; WT = wild type.
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expressions were reduced in ApoE−/− compared with
wild type mice. Interestingly, treatment with DIZE
increased both eNOS (Figure 4A, B) and nNOS
(Figure 4C, D) protein expressions, suggesting an
increase in NO bioavailability in the CC. Similar
results were obtained by immunostaining. We
observed that the eNOS expression was reduced
in penile endothelial cells identiﬁed by co-
immunostaining with CD31 (Figure 5A, B).
In order to conﬁrm the increased NO produc-
tion within erectile tissues by treatment with
DIZE, functional studies in the CC strip were
performed. As expected, the NO-dependent
relaxation induced by ACh was deeply reduced in
ApoE−/− when compared with wild type mice
(Figure 6A). Interestingly, the cavernosal relax-
ation induced by ACh was signiﬁcantly increased
by treatment with DIZE in ApoE−/− mice
Figure 4 Treatment with diminazene aceturate (DIZE) increases endothelial (eNOS) and neuronal (nNOS) nitric oxide
synthase expressions in penis from ApoE−/− mice. (A and C) Quantification of eNOS (A) and nNOS (C) protein expressions
was performed using western blotting in protein extracted from penis of wild type, untreated, and DIZE-treated apolipoprotein
E knockout (ApoE−/−). Representative western blotting gels of eNOS (B) and nNOS (D). Data were normalized using α-actin.
*P < 0.05 (one-way analysis of variance [ANOVA] followed by Bonferroni posttest). Each column represents the mean ± stan-
dard error of the mean (SEM) (n = 7 to 8) of relative protein expression in arbitrary unit (A.U.) from three independent
experiments. n.s. = nonsignificant; WT = wild type.
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when compared with vehicle group (Figure 6A).
Normalization of the ACh response with
the SNP (NO donor) evidenced even more
the beneﬁcial effect of ACE2 activation by
DIZE on NO bioavailability within the CC
(Figure 6B).
Treatment with DIZE Reduces Collagen Deposition
It has been reported that ApoE−/− mice have a
signiﬁcant increase in penile collagen content
[36,37]. Many studies have reported that ACE2
actions protect against pathological collagen depo-
sition in diverse organs [19,38]. Therefore, we
evaluated the effects of DIZE in penile ﬁbrosis of
ApoE−/− mice. Penile collagen content of ApoE−/−
mice was signiﬁcantly increased when compared
with wild type mice. The treatment with DIZE
produced a robust decrease in the collagen content
within the CC of ApoE−/− mice, returning it to
similar levels observed in the wild type mice
(Figure 7).
Beneficial Action of Treatment with DIZE on the CC
Is Not Accompanied by Reduction in Atherosclerotic
Plaque Size or Lipid Profile Changes
It has been reported that ACE2 has athero-
protective effects [39]. However, the treatment
with DIZE did not change atherosclerotic plaque
size (Figure 8A, B) or total cholesterol, LDL, and
HDL serum levels in ApoE−/− mice (Figure 8C–E).
These data indicate that the beneﬁcial effects of
ACE2 activation by DIZE in the CC were not
related to a decreased plaque deposition of lipid
proﬁle changes.
Discussion
The RAS is critically involved in the cardiovascu-
lar homeostasis, being an important target to
manage cardiovascular disorders [40,41]. This
system is also considerably involved in ED patho-
physiology [5,7,11]. Evidences indicate that RAS
acts in a paracrine manner in the erectile tissues
Figure 5 Treatment with diminazene aceturate (DIZE) increases endothelial nitric oxide synthase (eNOS) in vascular penile
endothelium and increases systemic nitric oxide (NO) bioavailability. (A–B) Immunostaining analysis was used to detect
eNOS expression in endothelial cells of dorsal penile vessels (arteries and vein). (C) Griess assay was used to determine
the NO metabolites, nitrite, and nitrate in mice serum. (A) The graphs show representative images. (B) Quantification of
eNOS expression. *P < 0.05 and **P < 0.01 (one-way analysis of variance [ANOVA] followed by Bonferroni posttest). Each
column represents the mean ± standard error of the mean (SEM) (n = 8) of relative protein expression in arbitrary unit (A.U.).
(C) Graphic showing the levels of nitrite and nitrate in serum from untreated and DIZE-treated apolipoprotein E knockout
(ApoE−/−) mice. *P < 0.05 (unpaired Student’s t-test). Each column represents the mean ± SEM (n = 10 to 12) of nitrite and
nitrate concentration (μmol/L).
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[4,7,8]. For instance, Becker et al. have shown that
Ang II levels in human CC are higher than in the
systemic plasma [4], which indicates an intense
modulation of the RAS within penis. Supporting
these data, it was observed that ACE activity were
30-fold higher in canine CC than carotid artery
[42]. Additionally, da Costa Goncalves et al.
observed that intracavernosal injection of A-779, a
Mas receptor antagonist, reduced the erectile
response in rats, indicating an endogenous role of
Ang-(1–7) in penile physiological erection [7].
Many components of the RAS such as AT1 recep-
tor, ACE, Ang I, Ang II, Ang III, Mas receptor, and
Ang-(1–7) were detected within the CC [7,8];
however, no study has addressed the expression
and activity of ACE2 in the penis. ACE2 is a key
enzyme of the RAS that breaks down the octapep-
tide Ang II and forms the heptapeptide Ang-(1–7)
[3,14]. Generally, the RAS is modulated by two
opposite branches, a constrictive and proliferative
axis, composed of Ang II/AT1 receptor, and a
vasodilatory and anti-proliferative axis, composed
of Ang-(1–7)/Mas receptor [43–45]. Therefore,
ACE2 modulates the balance of the two major
effectors of RAS, promoting beneﬁcial effects due
to an increased Ang-(1–7) production with con-
comitant degradation of Ang II [3,46]. In erectile
tissues, Ang II produces penile detumescence and
contributes to the development of ED [4], while
Ang-(1–7) mediates penile erection [7]. Thus, it
leads to the postulation that ACE2 would produce
beneﬁcial and pro-erectile actions in the penis. In
the present study, we found that ACE2 is present
within the mouse penis and that its reduction
may contribute to the erectile deﬁciency in
this hypercholesterolemic-induced ED. Moreover,
ACE2 activation protects the CC against
hypercholesterolemic-induced injuries.
The activation of ACE2 was achieved by phar-
macological treatment with DIZE. The concept of
ACE2 activators was recently developed by the
group of Prof. Raizada, which documented two
bioactive compounds, XNT [16] and DIZE [20].
These compounds are able to interact with speciﬁc
pockets in the structure of the enzyme (non-
catalytic sites) and favor the maintenance of the
optimal activity conformation [16]. Therefore,
they act by modulating ACE2 activity and, conse-
quently, shifting the levels of Ang II and Ang-(1–7)
[47]. Indeed, it has been shown that the beneﬁcial
cardiovascular actions of DIZE was abolished by
C-16, an ACE2 inhibitor [20,21], and attenuated
by co-treatment with A-779, an Ang-(1–7)-Mas
receptor antagonist [22,23]. Beyond activating
intrinsic ACE2, it has been shown that ACE2 acti-
vators, when given chronically, may also increase
the ACE2 expression [19,20]. The relevance of
each mechanism, intrinsic activation, or increase
in enzyme amount in a chronic scenario is still
unknown; however, both mechanisms imply the
increase of ACE2 activity. In the present study, the
levels of Ang II and Ang-(1–7) within the penis or
ACE2 activity were not evaluated, and the mecha-
nism by which DIZE protects erectile tissues
against hypercholesterolemic-induced injuries
should be carefully taken into account. Despite
this limitation, we observed that DIZE treatment
Figure 6 Angiotensin-converting enzyme 2 (ACE2) activa-
tion increases nitric oxide (NO) production within the corpus
cavernosum from apolipoprotein E knockout (ApoE−/−) mice.
Relaxation is produced by increasing cumulative concentra-
tions of acetylcholine (ACh) (A) in cavernosal strip from wild
type, untreated, and DIZE-treated ApoE−/− mice. (B) Normal-
ized curve response of ACh by SNP response at 10−4 mol/L.
**P < 0.01 and n.s. = nonsignificant (two-way analysis of
variance [ANOVA] followed by the Bonferroni’s multiple com-
parison test). Each point represents the mean ± standard
error of the mean (SEM) (n = 8). DIZE = diminazene
aceturate; SNP = sodium nitroprusside.
Diminazene Protects Corpus Cavernosum 297
J Sex Med 2015;12:289–302
increased ACE2 protein expression in the penis,
suggesting that this compound modulates,
somehow, ACE2 activity within the CC.
Many studies have pointed out that an aug-
mented oxidative stress is a critical pathway
involved in the impairment of cavernosal function
observed in ED [48]. An increased ROS produc-
tion may cause vascular impairment by decreasing
the ability of arteries to respond to vasodilation
factors [49,50]. ACE2 decreases vascular oxidative
stress by dual action, decreasing Ang II and
increasing Ang-(1–7) actions [44]. Ang II is a
classic pro-oxidant peptide that increases ROS
production through the activation of NADPH oxi-
dases [51]. On the other hand, Ang-(1–7) is an
antioxidant agent [52]. Acting thought Mas recep-
tor, this peptide reduces ROS production with
consequent improvement of endothelial function
[53]. In keeping with that, our study has shown
that the DIZE treatment normalized the aug-
mented ROS production observed in ApoE−/−
mouse penis, possibly by modulating NADPH
oxidase expression.
In addition to its role of decreasing ROS, DIZE
treatment also increased NO bioavailability in the
penis of ApoE−/− mice. NO is the main effector in
the erectile response and an impaired NO bioactiv-
ity is a major pathogenic mechanism of ED [54]. In
the present study, we found that treatment with
DIZE increased the stable NO metabolites NO2−/
NO3− in serum samples from ApoE−/− mice. More-
over, the expressions of eNOS and nNOS in the
penis of ApoE−/− mice were restored by treatment
with DIZE, suggesting that this compound
improves NO bioavailability within the penis. Sup-
porting these data, the functional study in
cavernosal strip revealed a marked increase in the
relaxation produced by ACh, which indicates an
enhanced production of NO in the DIZE-treated
group. Possibly, the beneﬁcial effect ofDIZE treat-
ment on NO generation is mediated by an increase
in local Ang-(1–7) levels. In fact, several studies
have reported that Ang-(1–7) improves endothelial
function by increasing NO bioavailability [55,56].
In our experimental protocol, DIZE was given
in the last 3 weeks, after 8 weeks of high-fat diet.
Previous reports have shown that after 6 weeks,
these animals have already developed atheroscle-
rosis in the aortic arc and carotid artery [57];
therefore, it is expected that cavernosal alterations
had already take place in the beginning of the
treatment. However, the direct evaluation of the
cavernosal condition at 8 weeks of high-fat
diet was not assessed, and the interpretation of
DIZE actions as reversing or preventive should be
carefully taken.
It has been shown that ACE2 has anti-
atherosclerotic activity [39,58]. This enzyme inhib-
its the development of atherosclerotic lesions,
reduces intraplaque inﬂammation, and increases
plaque stability [39,58,59]. Thus, the beneﬁcial
effects produced by ACE2 activation in the ApoE−/−
mouse penis could be due, in part, to a decrease in
atherosclerosis development or a lipid proﬁle
changes. However, in the present study, no signiﬁ-
cant differencewas observed in the lesion areawhen
Figure 7 Treatment with diminazene aceturate (DIZE) reduces penile fibrosis induced by hypercholesterolemia. Collagen
content was evaluated by Sirius red staining in penis from wild type and apolipoprotein E knockout (ApoE−/−) mice treated or
not with DIZE. (A) Quantification of collagen content into the corpus cavernosum. (B–G) Representative photomicrographs
of penis sections showing the collagen content (red staining). Figure parts B–D show the corpus cavernosum and E–F show
the dorsal vessels area. *P < 0.05 (one-way analysis of variance [ANOVA] followed by Bonferroni posttest). Each column
represents the mean ± standard error of the mean (SEM) (n = 10) of relative collagen content in arbitrary unit (A.U.).
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comparing DIZE-treated with untreated ApoE−/−
mice. Possibly, the duration of 3 weeks treatment
with DIZE was not sufﬁcient to establish/detect
changes on the development of atherosclerotic
plaques. Additionally, no modiﬁcation in lipid
proﬁle was observed.
In summary, our ﬁndings demonstrate that
ACE2 is expressed in the CC and its downre-
gulationwas associatedwith hypercholesterolemia-
induced ED. Furthermore, the treatment with
DIZE, a knownACE2activator compound, attenu-
ated ROS production and increased NO
bioavailability. Importantly, these effects were
accompanied by a reduction in penile collagen
content. These results suggest that ACE2 might
have signiﬁcant therapeutic beneﬁts for the treat-
ment of ED.
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